IL-7Rα pathway mutations provide potential targets for acute lymphoblastic leukemia therapy. In both T-ALL and BCP-ALL, mutations can occur at many points within the IL-7Rα signaling pathways (A). Aberrant signaling through these pathways offers multiple potential therapeutic targets (B).